Humira’s Patent Wall
Humira’s patent wall lengthens its monopoly term by $19+ years$.

Americans will spend an estimated $99$ billion on Humira from when its main patent expires (2016) until biosimilar versions are introduced (2023).
Pricing, Revenue, and Growth Forecast

Revenue for Humira in the U.S.

Indications: 11 total indications, major disease indications include rheumatoid arthritis (2003), psoriatic arthritis (2005), and Crohn’s disease (2007)

Price: Current non-discounted annual price is $44,000 per person

Trend: Price has increased over 100% from 2012 to 2018
Currently 39 years of patent protection
90% of patent applications filed after FDA approval

- 257 patent applications filed, 130 granted
- Patents granted give commercial exclusivity for 39 years
DELAYED COMPETITION IN THE U.S.

Europe:
- Within six months, prices dropped by 70% and the five biosimilar products had captured over 1/3 of the total market share.

U.S.:
- AbbVie has reached settlement deals to delay the launch of biosimilars until 2023.
- An estimated $77 billion will be spent on Humira in the U.S. from Oct 2018 until biosimilar entry in 2023.
THE COST OF OVERPATENTING

• AbbVie’s 130 granted patents in the U.S. will prohibit biosimilars from entering the market until 2023.

• By contrast, AbbVie has only been granted six patents on Humira in Europe, where significantly lower-cost biosimilar versions of Humira have been available since 2018.

• The additional five years of monopoly protection will cost Americans an estimated $77 billion.

More information on Humira is available at i-mak.org/humira